Abstract:A two-dimensional ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry （2D-UPLC-Q/TOF-MS） method was established for the separation and structural analysis of the components in teicoplanin. This method effectively solved the problems associated with chromatographic systems， such as liquid chromatography-mass spectrometry （LC-MS）， which used a non-volatile phosphate buffer as the mobile phase and were not suitable for the rapid identification of impurities. Moreover， this method circumvented the complexities associated with locating and identifying impurities using the original method by re-establishing a chromatographic system suitable for LC-MS. In this study， for one-dimensional （1D） chromatography， the chromatographic separation was performed on an Octadecyl silica （ODS） hypersil column （250 mm×4.6 mm， 5 μm） with gradient elution using 3.0 g/L sodium dihydrogen phosphate buffer （pH 6.0）/acetonitrile=9/1 （v/v） as mobile phase A and 3.0 g/L sodium dihydrogen phosphate buffer （pH 6.0）/acetonitrile=3/7 （v/v） as mobile phase B. The column temperature was maintained at 30 ℃ and an ultraviolet detector was used at 254 nm for analysis. For 2D chromatography， desalting was performed on a Waters ACQUITY UPLC BEH C18 column （50 mm×2.1 mm， 1.7 μm） with gradient elution using ammonium formate buffer （pH 6.0） and acetonitrile as the mobile phases. The column temperature was maintained at 45 ℃. The MS data for the components and impurities were collected by positive ion electrospray ionization （ESI） using the full-information tandem MS mode （MSE）. The cone and nebulizer gas flow rates were set at 50 and 900 L/h， respectively. The ion source and nebulizer gas temperatures were set at 120 ℃ and 500 ℃， respectively. The ESI and cone needle voltages were set at 2500 and 60 V， respectively. The collision energy was set at 20-50 eV. The molecular formulas of the components and impurities were determined using their exact masses and isotope distributions， and the structural components and impurities of teicoplanin were deduced from their fragment ions according to the fragmentation pathway of the TA2-2 component. Moreover， the 10 components reported in the European Pharmacopoeia 10.0 were analyzed and 22 impurities of teicoplanin were identified by 2D-UPLC-Q/TOF-MS. Three new impurities and two characteristic fragment ions of the teicoplanin parent nucleus were detected， and the fragmentation pathway of TA2-2 was deduced. Using this method， 1D-UPLC is applicable for the accurate qualification of components based on relative retention times， and 2D-UPLC-Q/TOF-MS is suitable for the rapid identification of the structure of components based on their fragment ions. The results indicate that 2D-UPLC-Q/TOF-MS may be used to analyze the structure of impurities in teicoplanin based on their exact masses， isotope distributions， and fragment ions. The method is rapid， simple， and sensitive， which provides a novel strategy for the quality control and process optimization of teicoplanin.

Analysis and Identification of the Impurities of Antineoplastic Agent MTC-220 by LC-MS/MS

Impurity Profile and Spectrum Characteristics of the Isomers in Cefamandole Nafate Using High- Performance Liquid Chromatography/high-Performance Size Exclusion Chromatography Tandem Ion Trap/time-of-flight Mass Spectrometry

Study on identification method of 14C -metsulfuron-methyl

Separation and Characterization of the Polymerized Impurities in Oxacillin Sodium by 2D HPSEC and HPLC IT-TOF MS

Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique.

Identification, Characterization, And Synthesis Of Process-Related Impurities In Antiproliferative Agent Tq-B3203

Separation and structural characterization of unknown impurity in vancomycin by two-dimensional preparative liquid chromatography, LC-MS and NMR

Impurity profiling of varenicline tartrate by LC-QTOF mass spectrometric techniques during drug development

[Analysis of teicoplanin impurities by two-dimensional ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry]

Identification and quantitative analysis of genotoxic impurities in rifampicin: Development and validation of a targeted LC-MS/MS method for 1-amino-4-methylpiperazine

Identification of a Novel Low-Level Impurity in Fungicide Pyraclostrobin by High-Performance Liquid Chromatography/tandem Mass Spectrometry

Isolation and identification of four major impurities in capreomycin sulfate.

Characterization of Elvitegravir and Its Related Impurities Using ESI–LC–MS, NMR Techniques, Method Development and Validation of Its Related Substances by HPLC Method

Characterization of the Trace-Level Impurities in the Bulk Drug Citalopram by High-Performance Liquid Chromatography/Tandem Multistage Mass Spectrometry

Identification and characterization of impurities in an insecticide, commercial chlorantraniliprole using liquid chromatography–tandem mass spectrometry

Accurate Identification of Degraded Products of Aflatoxin B1 Under UV Irradiation Based on UPLC-Q-TOF-MS/MS and NMR Analysis

Impurity profiling of Cefteram pivoxil based on Fourier transform ion cyclotron resonance MS

Structurally related impurity profiling of thiacloprid by orbitrap and de novo identification tool

Separation and Characterization of Synthetic Impurities of Triclabendazole by Reversed-Phase High-Performance Liquid Chromatography/electrospray Ionization Mass Spectrometry

Genotoxic Impurities: A Quantitative Approach

Identification of undescribed key impurities of homoharringtonine bulk drug